© Globe Newswire
08.12.2025
RXRX
LISTED
NASDAQ
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
News Preview
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP)....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
WVE
LISTED
NASDAQ
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
News Preview
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo g...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
COGT
LISTED
NASDAQ
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
News Preview
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggreg...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
08.12.2025
ABEO
LISTED
NASDAQ
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
News Preview
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Z...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
08.12.2025
PCVX
LISTED
NASDAQ
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
News Preview
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
OCUL
LISTED
NASDAQ
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
News Preview
Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
AGIO
LISTED
NASDAQ
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
News Preview
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
CRDF
LISTED
NASDAQ
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
News Preview
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is tak...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
News Preview
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
OBIO
LISTED
NASDAQ
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
News Preview
NEW HOPE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced three presentations at the 2025 Innovation in Cardiology Intervention (“IC...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2025
HBFG
LISTED
CSE
Happy Belly Food Group Announces Executive Leadership Plan to Support Next Phase of Growth
News Preview
Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce executive management updates to support its 2026 growth plan as the Company advances its objective of doubling the size of its...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
News Preview
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose -...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
08.12.2025
ONCO
LISTED
NEO
Onco-Innovations beauftragt Investmentbank mit der Prüfung einer Nasdaq-Notierung und eines möglichen gleichzeitigen Emissionsangebots
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es eine US-Investmentbank als Kapitalmarktberater beauftragt hat, um mit seiner Absicht eine mögliche zusätzliche Notierung (Cross-Listing) an der “Nasdaq Stock Market LLC” (Nasdaq oder die Börse) anzustreben und parallel eine mögl......
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
MNOV
LISTED
NASDAQ
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
News Preview
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amy...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
SNWV
LISTED
NASDAQ
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
News Preview
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
MDCE
LISTED
OTC
Medical Care Technologies (OTC Pink:MDCE) Positions Itself in the Multi-Billion Dollar AI Dermatology Market With Google-Backed Melanoma Detection Technology
News Preview
MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce a major technology advancement in the development of its soon-to-launch AI wound and skin monitoring platform. The Company has strategically aligned with Derm Foundation, a Google-backed pretrained dermatology imaging model, e...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
VIRP
LISTED
EURONEXT
Virbac : Declaration of the number of shares and voting rights 11/2025
News Preview
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
CASI
LISTED
NASDAQ
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
News Preview
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced data presented from its Phas...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
RGNT
LISTED
XASE
Regentis Biomaterials Commences Trading on NYSE: Set to Transform Cartilage Repair Market with Off-the-Shelf Regenerative Product
News Preview
Lead product GelrinC®, a hydrogel synchronized erosion and resorbable implant, the only restorative product for knee cartilage repair, is a breakthrough effective and economical procedure to address a large unmet needGelrinC is approved for knee cartilage repair in the European Union and is currently at midpoint in a pivotal FDA trial for the...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
LIXT
LISTED
NASDAQ
LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
News Preview
BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE (NASDAQ:LIXT) has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic angles for resistant cancers. The company built its early identity around that science, and for good reason. LB-100 remains one of the few agents capab...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
WGRX
LISTED
NASDAQ
Wellgistics Health Announces Launch of Diabetes Drug Brenzavvy(R) to Wellgistics Pharmacy Network
News Preview
Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash priceProprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to ed...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
006280
LISTED
KOE
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
News Preview
- First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombina...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
AVNT
LISTED
TSX
Avant Brands Fully Repays $9.5M Secured Convertible Debenture
News Preview
KELOWNA, BC / ACCESS Newswire / December 8, 2025 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, today announced the full repayment of its $9.5 million amended and restated convertible debenture (the "A&R Debenture&qu...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
GALD
LISTED
XWSX
Galderma Welcomes Increased Equity Investment From L’Oréal
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers).
Foll...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
SDZ
LISTED
XWSX
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
News Preview
Sandoz Group AG
/ Key word(s): Acquisition
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership 08.12.2025 / 07:00 CET/CEST
Expands in-house development and manufacturing capabilities for biosimilars, consolidating position as undisputed leader in the sector
Strengthens posi......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
EVT
LISTED
XETR
Evotec schließt Verkauf von Just – Evotec Biologics Toulouse Standort an Sandoz ab
News Preview
Alle Abschlussbedingungen wurden nach Ankündigung über die Vereinbarung eines nicht-bindenden Term Sheet im Juli und Unterzeichnung des Vertrags im November erfüllt
Die Vereinbarung beinhaltet rund 350 Mio. US$ in bar für die Just – Evotec Biologics Produktionsanlage in Toulouse sowie Vorab-Technologielizenzgebühren für Evotecs kontinuierliche ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
NWRN
LISTED
SIX
Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
News Preview
Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III clinical study designed to enroll at least 400 patients; topline results are ex......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
NWRN
LISTED
SIX
Newron gibt US-Start der globalen klinischen Phase-III-Studie ENIGMA-TRS 2 mit Evenamide als Zusatztherapie für Patienten mit behandlungsresistenter Schizophrenie (TRS) bekannt
News Preview
Newron gibt US-Start der globalen klinischen Phase-III-Studie ENIGMA-TRS 2 mit Evenamide als Zusatztherapie für Patienten mit behandlungsresistenter Schizophrenie (TRS) bekannt
ENIGMA-TRS 2 ist eine globale, randomisierte, doppelt verblindete, placebokontrollierte 12-wöchige klinische Phase-III-Studie, an der mindestens 400 Patienten teilnehmen so......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
EVT
LISTED
XETR
Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz
News Preview
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November
Agreement includes approximately US$ 350 m in cash for Just – Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec’s continuous manufacturing platform
In additio......
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GLPG
LISTED
EURONEXT
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
News Preview
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
News Preview
Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
IBAB
LISTED
EURONEXT
YAS Healthcare signs contract for a Proteus®ONE solution, the first proton therapy system to be installed in Dubai, UAE
News Preview
Louvain-La-Neuve, Belgium, December 8, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today it has signed a contract with YAS Healthcare, a subsidiary of DAS Holding, to install a Proteus®ONE1 c...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
2171
LISTED
HKSE
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
News Preview
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
CUV
LISTED
ASX
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
News Preview
EXECUTIVE SUMMARY...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
1801
LISTED
HKSE
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
News Preview
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, annou...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
EVT
LISTED
XETR
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
News Preview
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec's continuous manufacturing platformIn addition, Evotec...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
2171
LISTED
HKSE
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
News Preview
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
6855
LISTED
HKSE
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced th...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
13
LISTED
HKSE
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 20...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ONC
LISTED
NASDAQ
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematolo...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
IMMX
LISTED
NASDAQ
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
News Preview
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain inv...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
GPCR
LISTED
NASDAQ
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
News Preview
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the compan...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
IMMX
LISTED
NASDAQ
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
News Preview
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
TLX
LISTED
ASX
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosop...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
LLY
LISTED
NYSE
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
News Preview
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) populationProgression-free survival data were immature but trended in favor of pirtobrutinib with a 43% redu...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
LYEL
LISTED
NASDAQ
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced new clinical and translational data from the ongoing clinical trial of rondecabtagene au...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
REGN
LISTED
NASDAQ
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
News Preview
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
WVE
LISTED
NASDAQ
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
News Preview
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.12.2025
MSPR
LISTED
NASDAQ
MSP Recovery, Inc. Announces Conclusion of SEC Investigation: No Intention to Recommend Enforcement Action Against the Company, its CEO, John H. Ruiz, or its Officers
News Preview
MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the "Company"), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, announces that the staff of the U.S. Securities and Exchange Commission ("SEC") has informed the Company that it has concluded...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
LFCR
LISTED
NASDAQ
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders.
If you currently own Lifecore stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to t...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
CSL
LISTED
ASX
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
News Preview
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing i...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
News Preview
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Ph...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2025
RIGL
LISTED
NASDAQ
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
News Preview
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patientsRBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose groupSOUTH SAN FRANCISCO, Calif.,...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
INCY
LISTED
NASDAQ
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
News Preview
Incyte (Nasdaq:INCY) today announced new clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, for patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). These preliminary results are from the dose escalation...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
INCY
LISTED
NASDAQ
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
News Preview
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, for the treatment of patients with essential thrombocythemia (ET) harboring a Type 1 CALR mutation who are resistant or intole...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
GILD
LISTED
NASDAQ
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
News Preview
Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autol...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2025
GMAB
LISTED
NASDAQ
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
News Preview
Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study showed that treatment with EPKINLY + R2 reduce...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
PRME
LISTED
NASDAQ
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
News Preview
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company’s investigational autologous hematopoietic stem cell product...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
ALXO
LISTED
NASDAQ
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
News Preview
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2025
GMAB
LISTED
CPH
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
